Different DNA services can produce different Alzheimer's risk reports because they may analyze different APOE findings and use different testing methods. Neither result represents a person's complete chance of developing Alzheimer's disease. APOE is a gene involved in moving fats through the bloodstream. One form, called APOE ε4, increases susceptibility to late-onset Alzheimer's, but it cannot predict with certainty who will develop the disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does an Alzheimer's DNA report measure?
- Why can two services report different results?
- How should increased or reduced risk be read?
- Is this testing for inherited early-onset Alzheimer's?
- What should you do with conflicting reports?
What does an Alzheimer's DNA report measure?
Most consumer reports focus on APOE ε4. One copy raises susceptibility to late-onset Alzheimer's, and two copies raise it further. However, many carriers never develop Alzheimer's, while many people with the disease do not carry ε4.
The FDA describes 23andMe's authorized report as identifying an association between APOE ε4 and increased risk—not calculating a person's overall Alzheimer's risk. The FDA's direct-to-consumer testing guidance makes that limitation explicit. A report therefore describes one genetic risk factor. It is not a diagnosis, a forecast, or proof that cognitive symptoms come from Alzheimer's.
Why can two services report different results?
Services do not necessarily examine or present the same genetic information. FDA records say 23andMe reports APOE ε4, while the agency's Helix clearance documented six APOE genotype pairs and a different sequencing technology. That difference matters because reports can vary in scope.
One service may emphasize whether ε4 is present, while another may identify a specific pair of APOE variants. The wording and risk categories may consequently look different even when the reports concern the same gene. The FDA's Helix clearance decision also states that the report was not intended to diagnose disease or determine treatment. A comparison should start with what each test measured, not whether one displayed a higher-looking risk label.
How should increased or reduced risk be read?
An increased-risk result means a tested variant is associated with greater susceptibility. It does not mean Alzheimer's is present or inevitable. A reduced-risk result is not an all-clear because the test may omit other relevant variants and non-genetic influences. MedlinePlus Genetics explains that direct-to-consumer results are not comprehensive and that both increased- and reduced-risk findings are non-definitive.
Its guidance on interpreting consumer DNA results supports reading the result as one piece of evidence rather than a final answer. An APOE estimate also needs ancestry context. The Alzheimer's Association reports that ε4-related risk varies across racial and ethnic groups and that most earlier research focused on White participants. A numerical estimate may therefore appear more precise than the underlying evidence supports for some people.
Is this testing for inherited early-onset Alzheimer's?
No. An APOE consumer report concerns susceptibility to late-onset Alzheimer's. It should not be confused with testing for rare genetic mutations that directly cause inherited early-onset disease.
The great majority of Alzheimer's cases are late-onset. The Alzheimer's Association estimates that rare deterministic mutations—changes considered sufficient to cause the disease—account for 1% or less of cases. That distinction becomes especially important when a family has multiple cases beginning unusually early. An APOE result cannot confirm or rule out one of those rare inherited mutations.
What should you do with conflicting reports?
First, compare the underlying information rather than the headline risk labels: The Alzheimer's Association advises genetic counseling before ordering APOE testing and after receiving results. Its genetics guidance notes possible effects on relatives and concerns involving anxiety, insurance, employment, and discrimination.
- Check whether both reports list your two APOE variants.
- Note whether each service reports only ε4 status or a broader genotype pair.
- Do not change treatment or make diagnostic decisions from either consumer report.
- Bring the complete reports—not screenshots of summary labels—to a clinician or genetic counselor.
- Ask whether confirmatory prescription testing is appropriate before acting on the result.
